Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1201-1220 of 3,900 trials

Asciminib Roll-over Study for Leukemia Patients

We are examining the long-term safety of asciminib in patients with certain types of leukemia who have completed a previous study. This trial aims to see if continued treatment is beneficial for these patients.

Chronic Myeloid Leukaemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Thyroid Eye Disease: VRDN-001 Treatment Study

We are testing the safety and tolerability of a new monoclonal antibody, VRDN-001, in people with thyroid eye disease. This study involves receiving intravenous infusions to see how well the treatment is tolerated.

Thyroid Eye Disease1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesEndocrinologyOphthalmology

Advanced Tumor Cancer: ABBV-CLS-484 Treatment

We are studying a new treatment called ABBV-CLS-484 for people with advanced tumor cancer. The trial will explore its effects alone and in combination with other therapies.

Advanced Cancer>2 yearsSafety phase (I)Oncology

Extracranial Malignant Germ Cell Tumors: Carboplatin vs. Cisplatin

We are comparing the effectiveness and side effects of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumors. This study aims to improve treatment options and patient quality of life.

Malignant Extracranial Germ Cell Tumours>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Pneumococcal Vaccine Study for Infants: PCV21

We are investigating a new 21-valent vaccine for healthy infants starting at 2 months old. The study aims to see if it works as well or better than the current vaccine in protecting against pneumonia.

Pneumococcal ImmunizationConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesPediatrics

Asthma and COPD: GB-0895 Study

We are investigating the safety of a new drug, GB-0895, in patients with mild to moderate asthma and those with COPD. This study aims to understand how well the drug is tolerated in these groups.

Mild to Moderate AsthmaChronic Obstructive Pulmonary Disease (COPD)>2 yearsSafety phase (I)Pulmonology

Systemic Lupus Erythematosus: CABA-201 T Cell Therapy

We are studying a new T cell therapy for people with active systemic lupus erythematosus to see if it is safe and effective. This research aims to understand how it affects disease activity and overall health.

Systemic Lupus Erythematosus>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyRheumatology

Vertebral Osteomyelitis: Early Oral Antibiotics Study

We are investigating if switching to oral antibiotics after one week is as effective as continuing intravenous treatment for pyogenic vertebral osteomyelitis. This study will also assess safety, hospital stays, and quality of life for patients.

Pyogenic Vertebral Osteomyelitis3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesOrthopedics and TraumatologyRheumatology

Hepatitis B: TherVacB Vaccine Study

We are testing a new vaccine for adults with hepatitis B to see if it is safe and how well it boosts the immune response. The study will also check if it helps reduce the virus in the body.

Chronic Hepatitis B6-12 monthsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHepatologyInfectious Diseases

Multiple Sclerosis: Ocrelizumab Access Study

We are exploring how multiple sclerosis impacts patients physically while ensuring they can continue receiving ocrelizumab treatment. This study also looks at the safety and tolerability of the medication.

Multiple Sclerosis>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineNeurology

Chronic Lymphocytic Leukemia: ABBV-453 Study

We are assessing how the oral medication ABBV-453 affects adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The study focuses on understanding its side effects and how it moves through the body.

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma>2 yearsSafety phase (I)Oncology

HER3-DXd for Advanced Solid Tumors

We are studying a new treatment for patients with locally advanced or metastatic solid tumors to see if it is effective and safe. This trial will help us understand how well it works and its relationship with tumor characteristics.

Locally Advanced or Metastatic Solid Tumors>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Breast Imaging: Iodine Contrast Study

We are investigating how effective and safe iodine-based contrast agents are in enhancing mammograms and breast MRIs. This study aims to improve imaging quality for women undergoing these tests.

Breast Cancer>2 yearsConfirmation phase (III)Oncology

Infectious Endocarditis: Shorter Antibiotic Treatment Study

We are investigating whether a shorter course of antibiotics is safe and effective for treating left-sided infectious endocarditis caused by specific bacteria. This study also looks at the potential cost benefits of this accelerated treatment.

Infectious Endocarditis≤3 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInfectious Diseases

MB-CART19.1 for Refractory Systemic Lupus Erythematosus

We are testing a new treatment for patients with systemic lupus erythematosus that has not responded to standard therapies. The goal is to see if this new approach can provide better outcomes.

Systemic Lupus Erythematosus>2 yearsSafety phase (I)Efficacy phase (II)Rheumatology

Membranous Nephropathy: Dapagliflozin Treatment Study

We are investigating how dapagliflozin affects immune activity and kidney function in patients with Membranous Nephropathy. This study may help us understand its potential benefits for managing this condition.

Membranous Nephropathy1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology

Myotonic Dystrophy Type I: Metformin Study

We are investigating whether metformin can improve muscle and overall function in patients with Myotonic Dystrophy Type I. The study will also assess the safety of metformin and its effects on quality of life.

Myotonic Dystrophy Type 1 (DM1)>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Inclusion Body Myositis: Ruxolitinib Treatment Study

We are investigating whether ruxolitinib can improve movement and muscle function in patients with Inclusion Body Myositis. The study also looks at safety and quality of life for participants.

Inclusion Body Myositis>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyRheumatology

Prostate Cancer: [225Ac]Ac-PSMA-R2 Treatment Study

We are studying a new treatment for men with advanced prostate cancer to see if it is safe and effective. This trial includes men who have been treated before and those who have not.

Advanced Prostate CancerSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Chronic Myeloid Leukemia: TERN-701 Treatment

We are evaluating a new treatment called TERN-701 for individuals with chronic myeloid leukemia. The study aims to assess its safety and how well it works compared to existing options.

Chronic Myeloid Leukemia>2 yearsSafety phase (I)Oncology